$XFOR

X4 Pharmaceuticals (XFOR) reported blinded data from its 4WARD study, showing promising results for mavorixafor in treating chronic neutropenia. The company plans to initiate a Phase II study (4STEPS) in 2027 to evaluate G-CSF reduction. X4 estimates a 15,000-patient U.S. market opportunity, with potential expansion to 30,000 patients. Clinicians highlighted the high disease burden and need for new treatments.

X4 Pharmaceuticals, Inc (XFOR) filed an SEC Form 8-K — Other Events. Virtual Investor Day October 29, 2026 Nasdaq: XFOR Exhibit 99.1 2 This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer sessi

Craig Adam R (Executive Chairman) purchased 4,600 shares of X4 Pharmaceuticals, Inc (XFOR) at $2.58 on 2026-10-16.

X4 Pharmaceuticals (XFOR) will host a virtual Investor Day on October 29, 2026, to discuss mavorixafor as a potential treatment for chronic neutropenia. The company will review the Phase 3 4WARD trial and outline a planned Phase 2 trial. Key opinion leaders in hematology will participate in discussions about the drug's potential commercial opportunity.

X4 Pharmaceuticals, Inc (XFOR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures - Repayment of Existing Loan Facility Completed - - Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enr

X4 Pharmaceuticals (XFOR) secured a $150M senior debt facility with K2 HealthVentures, replacing a prior loan. $80M was used to repay existing debt, with $70M available. Funds support corporate activities and potential mavorixafor launch. X4 expects Phase 3 trial enrollment completion by year-end 2026 and topline data in H1 2028.

X4 Pharmaceuticals (XFOR) issued 80,000 stock options to new employees under its 2019 Inducement Equity Incentive Plan. The options have a 10-year term, a $2.90 exercise price, and vest over 4 years. The company focuses on rare hematology diseases and is conducting a Phase 3 trial for mavorixafor, its lead drug.

X4 Pharmaceuticals (XFOR) reported a positive FDA Type C meeting outcome, reducing the 4WARD Phase 3 trial sample size from 176 to 126 participants. The FDA agreed the revised size maintains adequate power. The company expects enrollment completion by year-end 2026 and topline data in H1 2028. Mavorixafor targets chronic neutropenia, a rare disease with limited therapy options.

Volpone John (President) sold 24,576 shares of X4 Pharmaceuticals, Inc (XFOR) at $4.44 ($0.11M total) on 2026-08-12.

Craig Adam R (Executive Chairman) sold 47,436 shares of X4 Pharmaceuticals, Inc (XFOR) at $4.44 ($0.21M total) on 2026-08-12.